| Title: | Genetic Variation in Targets of Antidiabetic Drugs and Alzheimer Disease Risk |
| Journal: | Neurology |
| Published: | 2 Jun 2022 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/35654594/ |
| DOI: | https://doi.org/10.1212/wnl.0000000000200771 |
| URL: | https://n.neurology.org/content/neurology/99/7/e650.full.pdf |
Publication 14007
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BACKGROUND AND OBJECTIVES: Previous studies have highlighted antidiabetic drugs as repurposing candidates for Alzheimer disease (AD), but the disease-modifying effects are still unclear.</p>
METHODS: A 2-sample mendelian randomization study design was applied to examine the association between genetic variation in the targets of 4 antidiabetic drug classes and AD risk. Genetic summary statistics for blood glucose were analyzed using UK Biobank data of 326,885 participants, whereas summary statistics for AD were retrieved from previous genome-wide association studies comprising 24,087 clinically diagnosed AD cases and 55,058 controls. Positive control analysis on type 2 diabetes mellitus (T2DM), insulin secretion, insulin resistance, and obesity-related traits was conducted to validate the selection of instrumental variables.</p>
RESULTS: In the positive control analysis, genetic variation in sulfonylurea targets was associated with higher insulin secretion, a lower risk of T2DM, and an increment in body mass index, waist circumference, and hip circumference, consistent with drug mechanistic actions and previous trial evidence. In the primary analysis, genetic variation in sulfonylurea targets was associated with a lower risk of AD (odds ratio [OR] = 0.38 per 1 mmol/L decrement in blood glucose, 95% CI 0.19-0.72, p = 0.0034). These results for sulfonylureas were largely unchanged in the sensitivity analysis using a genetic variant, rs757110, that has been validated to modulate the target proteins of sulfonylureas (OR = 0.35 per 1 mmol/L decrement in blood glucose, 95% CI 0.15-0.82, p = 0.016). An association between genetic variations in the glucagon-like peptide 1 (GLP-1) analogue target and a lower risk of AD was also observed (OR = 0.32 per 1 mmol/L decrement in blood glucose, 95% CI 0.13-0.79, p = 0.014). However, this result should be interpreted with caution because the positive control analyses for GLP-1 analogues did not comply with a weight-loss effect as shown in previous clinical trials. Results regarding other drug classes were inconclusive.</p>
DISCUSSION: Genetic variation in sulfonylurea targets was associated with a lower risk of AD, and future studies are warranted to clarify the underlying mechanistic pathways between sulfonylureas and AD.</p>
10 Keywords
- Alzheimer Disease
- Blood Glucose
- Diabetes Mellitus, Type 2
- Drug Repositioning
- Genome-Wide Association Study
- Glucagon-Like Peptide 1
- Humans
- Hypoglycemic Agents
- Mendelian Randomization Analysis
- Polymorphism, Single Nucleotide
7 Authors
- Bowen Tang
- Yunzhang Wang
- Xia Jiang
- Madhav Thambisetty
- Luigi Ferrucci
- Kristina Johnell
- Sara Hägg
Enabling scientific discoveries that improve human health